European Congress on

Vaccines & Vaccination

Theme: The Current Challenges in Vaccine Research and Development

Event Date & Time

Event Location

Amsterdam, Netherlands

16 years of lifescience communication

Performers / Professionals From Around The Globe

Tracks & Key Topics

Euro Vaccines 2018

About Conference

Vaccines Committee delighted to welcome all the interested and enthusiastic participants across the globe to its prestigious ‘European Congress on Vaccines & Vaccination’ to be held during August 23-24, 2018 at Amsterdam, Netherlands. which highlights the theme “The Current Challenges in Vaccine Research and Development”. Euro Vaccines 2018 is a two day conference concentrating on Interactive Sessions & Sub-sessions emphasized on innovation and new trends on vaccines, keynote lectures from Senior Scientists and industry experts, panel discussions, poster competitions and Young Researcher Forum. The conference program will feature well-known and thought provoking speakers to interactive discussion sessions, prompt keynote presentations, Oral talks, Poster presentations and Exhibitions  

Why to attend??

The Vaccine & Vaccination conference interacts with members across the globe focused on learning about vaccines and its specialties. This is the single best opportunity to reach the largest participants. Sharing the knowledge and demonstrations, information and B2B meetings with industrialists and potential clients to make a splash with innovative products live and brand recognition at this event. World renowned speakers, the most recent techniques, and the latest updates on vaccines are hallmarks of this conference.

EuroSciCon is the longest running independent life science events company with a predominantly academic client base. Our multi-professional and multi-speciality approach creates a unique experience that cannot be found with a specialist society or commercially.

Euroscicon are corporate members of the following Organizations

Royal Society of Biology
IBMS
British Society for Immunology
Rare Care UK
Opportunities for Conference Attendees
For Researchers & Faculty
Speaker Presentations
Poster Display
Symposium hosting
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students & Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Companies:

Exhibitor and Vendor booths
Sponsorships opportunities
Product launch
Workshop organizing
Scientific Partnering

Marketing and Networking with clients

Euroscicon organizes International Vaccine Meetings annually across Europe, Austria, Ireland, Germany, France, Liechtenstein, Lithuania, Finland, Luxembourg, Hungary, Italy, Norway, Poland, Denmark, Macedonia, Greece, Portugal, Romania, Czech Republic, Switzerland, United Kingdom, Belgium, Scotland, Latvia, Ukraine, Sweden, Denmark, Spain, Netherlands Russia, Bulgaria, France, with solitary subject of quickening logical revelations.

Session/Tracks

Novel Vaccines - Research and Development:

Vaccine examine and improvement has been gradually created from the little pox human immunization to human antibodies for rabies, lockjaw, typhoid, yellow fever, flu, chicken pox, hepatitis An, intestinal sickness, ebola and dengue fever as the timetable from eighteenth to 21st century. It is a movement that spotlights on an assortment of mechanical activities, which upgrade and advance enhanced most recent framework and practices for immunization use and wellbeing. Vaccine improvement is a long, complex process, regularly enduring 10-15 years and including a mix of open and private contribution. So we should survey every one of the disappointments to learn keeping in mind the end goal to defeat the present difficulties in the immunization advancement by institutionalized the methods and controls likewise. This will enhance the vaccination of human populace.

  • Therapeutic vaccination for auto immune diseases
  • Vaccine clinical trials
  • Feline leukemia vaccines
  • Vaccine management & quality assurance
  • Ebola outbreak

Cancer Vaccines:

Malignancy immunizations are a kind of organic treatment. Research here is at a beginning time and antibodies are predominantly accessible as a feature of clinical trials. The greater part of us think about immunizations given to solid individuals to help avert diseases, for example, measles and chicken pox. These immunizations utilize debilitated or eliminated germs like infections or microorganisms to begin a safe reaction in the body. Preparing the safe framework to guard against these germs enables keep to individuals from getting contaminations.

Most tumor antibodies work a similar way; however they influence the individual's safe framework to assault malignancy cells. The objective is to help treat malignancy or to help shield it from returning after different medications. In any case, there are additionally a few antibodies that may really help keep certain growths.

  • Vaccine Immunoinformatics
  • Cancer treatment vaccines
  • Cancer vaccines research
  • Cancer immunotherapy biomarkers
  • Non-specific cancer immunotherapies and adjuvants
  • CAR T-Cell therapy

Future Challenges & Current Research:

Vaccine advancement stays testing as a result of the profoundly modern avoidance components of pathogens for which immunizations are not yet accessible. Late years have seen the two triumphs and disappointments of novel Vaccine plan and the quality of iterative methodologies is progressively valued. These consolidate revelation of novel antigens, adjuvants and vectors in the preclinical stage with computational examinations of clinical information to quicken Vaccine outline. Invert and auxiliary vaccinology have uncovered novel antigen hopefuls and atomic immunology has prompted the detailing of promising adjuvants. Quality articulation profiles and insusceptible parameters in patients, antibodies and solid controls have shaped the reason for bio-marks that will give rules to future immunization plan.

  • Chloroplast-derived viral antigens
  • Expanded testing and modeling of vaccine
  • Aspects of pathology and host responses
  • Immunization routes
  • Antigen discovery
  • Immunological challenges

Vaccines Formulation & Discovery:

The Vaccine Formulation and Delivery investigate amass expects to enhance antibodies by growing new definitions and conveyance instruments. Research concentrates on the disclosure and advancement of new adjuvants, the improvement of immunizations for particular populaces (e.g. neonates and the elderly), and understanding antibody maintenance and circulation in the body. New conveyance strategies are likewise being examined including the utilization of viral and bacterial vectors, mucosal conveyance, and the improvement of without needle and topical immunizations.

  • TB vaccine (BCG)
  • Rotavirus vaccine
  • Diphtheria, tetanus, acellular pertussis vaccine
  • Inactivated polio
  • Measles vaccine
  • Influenza (flu) vaccine
  • Human papillomavirus vaccine (HPV cervical cancer)

DNA Vaccines:

DNA inoculation is a system for securing against sickness by infusion with hereditarily designed DNA so cells specifically create an antigen, delivering a defensive immunological reaction. DNA antibodies have potential preferences over ordinary immunizations, including the capacity to initiate a more extensive scope of safe reaction sorts. A few DNA immunizations are accessible for veterinary utilize. As of now no DNA antibodies have been endorsed for human utilize. Research is exploring the approach for viral, bacterial and parasitic illnesses in people, and also for a few diseases.

  • Plasmid vector
  • DNA vaccines delivery
  • Mechanistic basis for DNA-raised immune responses
  • Recombinant protein vaccines
  • Modulation of immune response

Novel Vaccines - Production & Development:

Immunizations are among the best accomplishments of current medication, prompting the annihilation of normally happening smallpox, the close disposal of polio and the control of infections, for example, rotavirus and hepatitis An and B in industrialized nations. Ordinary antibodies, in any case, ensure against a set number of irresistible sicknesses and, now and again, give deficient security. Successful immunizations against normal contaminations, for example, HIV, hepatitis C and intestinal sickness remain a neglected medicinal need. These holes, together with the risk of resurgence of killed sicknesses, add to the developing requirement for the advancement of new immunizations and the change of existing ones. Roughly 250 researchers and immunization specialists from around the globe assembled at Cambridge Healthtech Institute's third Annual Immunotherapeutics and Vaccine Summit (ImVacS 2008) to show the most recent advancements in this field and to talk about, in 64 introductions, the difficulties and flow ways to deal with improvement and generation of novel antibodies.

  • Production using plant, insect cells or bacteria cultures
  • Clinical development of vaccines
  • Investigational vaccines manufacture
  • Mammalian cells-based vaccines
  • Egg-based vaccines

Vaccine Delivery Systems and Adjuvants:

Routinely the proficiency of an adjuvant is measured by the ability to instigate upgraded Vaccine serum titres and cell interceded invulnerability (CMI) to a given antigen. These days the limit of an adjuvant is measured by the quality and in addition the greatness of the initiated invulnerable reaction, guided by the defensive insusceptible reaction required. Quality incorporates isotype and IgG subclass reactions, T-partner cell reactions described by the cytokine profile and cytotoxic T cells (CTL). In the early period of inoculation a few adjuvants impact the antigen organization and take-up by a purported terminal impact exemplified by aluminum hydroxide gel and oil adjuvants, which conceivably isn't as wanted as alledged. An advanced terminal is applied by moderate discharge definitions persistently discharging the antigen over some stretch of time or by beats at interims going for 'single infusion' immunization. Incredible endeavors are made to figure effective conveyance definitions focusing on the antigens from the site of organization, to depleting lymph hubs or removed lymphatic tissue or to mucosal surfaces by parenteral or mucosal organizations. These days, non-repeating bearers other than imitating immunizations are planned to incite mucosal insusceptible reactions including secretory IgA and CMI.

  • Inulin-derived adjuvant
  • Cytokines as adjuvants
  • Bacteria-derived adjuvants
  • Tensoactive adjuvants
  • Organic & inorganic adjuvants
  • Aluminum in vaccines
  • Latest techniques and advancements in vaccines delivery systems

Hepatitis, HIV and STD Vaccines:

People who have a STD are no less than two to five times more probable than uninfected people to obtain HIV disease on the off chance that they are presented to the infection through sexual contact. Furthermore, if a man who is HIV constructive likewise has a STD, that individual will probably transmit HIV through sexual contact than other HIV-tainted people.

Hepatitis B infection (HBV) and HIV are bloodborne infections transmitted principally through sexual contact and infusion medicate utilize. As a result of these common methods of transmission, a high extent of grown-ups in danger for HIV contamination are likewise in danger for HBV disease. HIV-constructive people who wind up noticeably contaminated with HBV are at expanded hazard for creating incessant HBV disease and ought to be tried. Moreover, people who are co-contaminated with HIV and HBV can have genuine restorative intricacies, including an expanded hazard for liver-related grimness and mortality.

Hepatitis C Virus (HCV) is a standout amongst the most widely recognized reasons for interminable liver ailment in the United States. For people who are HIV contaminated, co-disease with HCV can bring about a more quick event of liver harm and may likewise affect the course and administration of HIV contamination.

  • Innovations in HIV vaccine discovery
  • Emerging clinical trials
  • Viral vaccine vectors
  • B cell-based vaccines
  • T cell-based vaccines
  • HIV vaccine strategies
  • Challenges on AIDS vaccines development
  • Innate & mucosal immunity

Vaccination for Emerging and Re-emerging Diseases:

All through history, people have looked to comprehend the human body and cure illnesses. Since the acknowledgment that sickness can be caused by contamination and the foundation of Koch's hypothesizes, intended to show that a particular organism causes an illness, people have tried to distinguish and "cure" ailments. In any case, while we have been fruitful as an animal types at creating medications for various organisms, infections, and even parasites, unadulterated cures that anticipate future reinfection have stayed tricky. Undoubtedly, the main human sickness that has been killed in the advanced period (smallpox) was dispensed with through the fruitful improvement and utilization of deterrent antibodies, not the execution of any treatment methodology. Moreover, the two next probably possibility for annihilation, dracunculiasis (guinea worm malady) and poliomyelitis (polio), are moving toward this status using precaution measures, by means of water filtration and inoculation, individually. Truth be told, in spite of the current pushback from a deductively unwarranted hostile to vaxxers development, the utilization of an institutionalized inoculation regimen has prompted clear diminishments in infection rate of various youth infirmities in the Americas, including measles, mumps, rubella, and numerous others. Along these lines, in spite of the fact that the advancement of anti-microbials and other medicinal intercessions have significantly enhanced human wellbeing, immunizations remain the highest quality level of protection treatment for the capability of infection disposal. By Centers for Disease Control and Prevention [Public domain], by means of Wikimedia Commons.

  • Genome-based reverse vaccinology
  • Reverse genetics
  • Peptide vaccines
  • Recombinant DNA technology
  • Malaria and tuberculosis
  • Viral and bacterial pathogens

Biodefense Vaccine against Bioterrorism:

In assessing the part of immunizations for ensuring the non military personnel populace, very unique answers are come to. In spite of the defensive adequacy of antibodies against singular living beings, the high expenses and the considerable troubles associated with inoculating extensive populaces, alongside the expansive range of potential operators, make it difficult to utilize immunizations to secure the all inclusive community against bioterrorism. In this way, antibodies can't be viewed as a first line of guard against bioterrorism for the all inclusive community, as they can be for the generally little military populace. In any case, if reasonable antibodies can be made accessible, they have a few potential uses: control of a smallpox scourge and avoidance of a worldwide pandemic, postexposure prophylaxis against Bacillus anthracis (with anti-infection agents), and preexposure prophylaxis in people on call at high hazard, research center specialists, and social insurance suppliers.

  • Anthrax and smallpox
  • Plague and tularemia
  • Ebola, marburg, lassa, and machupo virus
  • Q fever, ricin toxin, typhus fever
  • Nipah virus

Vaccines for Immune Mediated Diseases:

Patients with safe interceded incendiary sicknesses (IMID, for example, RA, IBD or psoriasis, are at expanded danger of contamination, halfway in view of the illness itself, yet generally in light of treatment with immunomodulatory or immunosuppressive medications. Despite their hoisted chance for antibody preventable sickness, inoculation scope in IMID patients is shockingly low. This survey outlines current writing information on antibody security and viability in IMID patients treated with immunosuppressive or immunomodulatory tranquilizes and figures best-rehearse proposals on immunization in this populace. Particularly in the present time of organic treatments, including TNF-blocking operators, unique thought ought to be given to inoculation systems in IMID patients. Clinical proof demonstrates that vaccination of IMID patients does not expand clinical or research center parameters of infection movement. Live immunizations are contraindicated in immunocompromized people, yet non-live antibodies can securely be given. Despite the fact that the decreased nature of the invulnerable reaction in patients under immunotherapy may negatively affect immunization viability in this populace, sufficient humoral reaction to inoculation in IMID patients has been exhibited for hepatitis B, flu and pneumococcal inoculation. Immunization status is best checked and refreshed before the begin of immunomodulatory treatment: live antibodies are not contraindicated around then and inactivated antibodies evoke an ideal invulnerable reaction in immunocompetent people.

  • Central nervous system-targeted & tissue-specific autoimmunity
  • Vaccines for immunodeficiency diseases
  • Vaccines for autoimmune skin disorders & neuropathies
  • Vaccine safety
  • Vaccination strategy in patients with IMID
  • Innate immunity and diabetes vaccines

Vaccines for Pregnant Women and Neonates:

Immunizations can help keep you and you're developing family solid. On the off chance that you are pregnant or arranging a pregnancy, the particular immunizations you require are controlled by elements, for example, your age, way of life, restorative conditions you may have, for example, asthma or diabetes, sort and areas of travel, and past inoculations. CDC has rules for the immunizations you require some time recently, amid, and after pregnancy. A few antibodies, for example, the measles, mumps, rubella (MMR) immunization, ought to be given a month or more before pregnancy. You ought to get a few antibodies, as Tdap (to secure against whooping hack), amid your pregnancy.

The Advisory Committee on Immunization Practices (ACIP) suggests that all youngsters get their first dosage of Hepatitis B antibody during childbirth and finish the antibody arrangement by age 6– year and a half. More established kids and teenagers who did not already get the Hepatitis B immunization ought to likewise be inoculated.

  • Immunization during or before pregnancy / delivery
  • HIV and other STD vaccines for pregnant women
  • Influenza vaccination of pregnant women and protection of their infants
  • HPB, HAV, HBV vaccination for neonates
  • Whooping cough vaccines in pregnant women
  • Halting vaccination in pregnancy
  • Chiropractic vaccination care in women and pregnancy

Antibodies: Engineering and Therapeutics:

Antibodies, likewise called immunoglobulins, are huge Y-molded proteins which capacity to distinguish and help expel outside antigens or targets, for example, infections and microscopic organisms. Antibodies are delivered by particular white platelets called B lymphocytes (or B cells). At the point when an antigen ties to the B-cell surface, it animates the B cell to separate and develop into a gathering of indistinguishable cells called a clone. The develop B cells, called plasma cells, emit a huge number of antibodies into the circulatory system and lymphatic framework. Each extraordinary Vaccine perceives a particular outside antigen. This is on the grounds that the two hints of its "Y" are particular to every antigen, enabling diverse antibodies to tie to various remote antigens. Antibodies are created by the safe framework in light of the nearness of an antigen. Immunization designing has turned into an all around created train, enveloping disclosure techniques, generation procedures, and adjustment systems that have delivered clinically examined and advertised therapeutics. The acknowledgment of the long-standing objective of generation of completely human monoclonal antibodies has concentrated serious research on the clinical work of this powerful medication class.

  • Antibody biology & engineering
  • Antibodies as drugs
  • Antibody-targeted fusion proteins for cancer therapy
  • Genetics and epigenetics of the immune system
  • Antibodies and neuroscience
  • Monoclonal antibodies and organ cancers

Animal Models and Clinical Trials:

A human T-lymphotropic infection sort I/II (HTLV-I/II) immunization is vital in perspective of two etiologically related, perilous maladies, to be specific, grown-up T-cell leukemia/lymphoma and tropical spastic paraparesis/HTLV-I-related myelopathy. At the point when the danger of creating immune system maladies, for example, uveitis, polymyositis, and joint inflammation is incorporated, one can evaluate the long lasting danger of contaminated people to build up a HTLV related pathology as roughly 10%. The populaces in danger are, in a vast lion's share, from creating nations however the plague of HTLV-II disease in intravenous medication clients (IVDU) speaks to a conceivable supply for dispersal in the all inclusive community. The quantity of HTLV-I-contaminated people (15 to 25 million), together with the seriousness of related infection, legitimizes the improvement of an antibody. Distinctive antibody arrangements have been produced, utilizing for the most part recombinant pox and adenoviruses, however DNA plasmid innovation will soon turn into an attainable approach. Different creature models exist for trial viral contaminations, including rats, rabbits, or monkeys, however up to now, neither hematological nor neurological disarranges have been prompted by HTLV disease in such creature models. For long haul assurance from HTLV-I-related illnesses, inoculation ought to instigate both killing antibodies and particular cell-interceded invulnerability. This will require the consolidation of both env and stifler coding arrangements in the immunization arrangements. Preventive clinical trials may include distinctive partners of seronegative young ladies from endemic ranges preceding sexual action and IVDU in the industrialized world. In parallel, one ought to consider remedial immunization trials in HTLV-I-positive moms and IVDU to ensure them against ailment improvement. The watched rate of seroconversion in these distinctive accomplices makes such trials practical.

  • Animal models in vaccine development
  • Innovations and clinical trials in vaccination
  • Diagnostic and clinical applications
  • Engineered mouse models in cancer
  • Research and development of viral vaccines, including field trials

Market Report

Euro Vaccine 2018 welcomes attendees, presenters, and exhibitors from all over the world to Amsterdam, Netherlands. We are delighted to invite you all to attend and register for the “European Congress on Vaccines & Vaccination” which is going to be held during August 23-24, 2018 at Amsterdam, Netherlands

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at Euro Vaccine 2018, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Vaccines organizing committee look forward to meeting you in Amsterdam.

Importance & Scope:

Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) and Type - Forecast to 2022", The antibodies showcase is relied upon to achieve USD 49.27 Billion by 2022 from USD 34.30 Billion of every 2017, at a CAGR of 7.5%. The development of the market is ascribed to the rising predominance of illnesses, expanding government and nongovernment subsidizing for antibody improvement, and expanding ventures by organizations.

In view of innovation, the Vaccines showcase is divided into conjugate antibodies, inactivated and subunit Vaccines, live lessened antibodies, recombinant antibodies, and toxoid antibodies. In 2017, the conjugate section is relied upon to represent the biggest offer of the antibodies advertise. The development in this market is for the most part determined by expanding speculations by the legislature of creating countries and rising pervasiveness of irresistible maladies.

In 2017, North America is required to rule the market. The huge offer of this topographical portion is ascribed to elements, for example, expanding ventures by government associations and organizations to advance inoculation and additionally grow new Vaccines. In 2017, Europe is relied upon to hold the second biggest offer of this market. Factors, for example, accessibility of subsidizing and funding ventures for the advancement of new antibodies and expanding government activities are required to drive advertise development in this locale.

The investigation appraises the antibodies advertise estimate for 2017 and ventures its request till 2022. In the essential research process, different sources from both request side and supply side were met to acquire subjective and quantitative data for the report. Essential sources from the request side incorporate different industry CEOs, VPs, showcasing chiefs, innovation and development executives, and related key officials from the different players in the Vaccine advertise. For the market estimation process, both best down and base up approaches were utilized to gauge and approve the market size of the worldwide market and in addition to assess the market size of different other ward submarkets. Every single conceivable parameter that influence the market shrouded in this examination contemplate have been represented, seen in broad detail, confirmed through essential research, and broke down to get the last quantitative and subjective information. This information was combined and added to itemized sources of info and investigation.

Euro Vaccine 2018 is an international platform for presenting research about Novel Vaccines - Research and Development, Cancer Vaccines, Vaccines Formulation & Discovery, DNA Vaccines, Novel Vaccines - Development and Production, Vaccine Delivery Systems and Adjuvants, Hepatitis, HIV and STD Vaccines, Vaccination for Emerging and Re-emerging Diseases, Biodefense Vaccine against Bioterrorism, Vaccines for Immune Mediated Diseases, Vaccines for Pregnant Women and Neonates, Antibodies : Engineering and Therapeutics, Animal Models and Clinical Trials, Future Challenges & Current Research and Others for the benefit of both the academia and business. This event brings together world class scientists, Researchers and Academicians to explore the recent advancements that are taking place in the field of Vaccines & Vaccination.

 

Why Amsterdam?

Rated one of Europe's top destinations, a visit to Amsterdam means a schedule packed full of museums, attractions, nightlife and more. Here you will find plenty of information to offer your clients a unique and memorable visit to Amsterdam.

An iconic city that offers your guests plenty to see and do, The Amsterdam Metropolitan Area is home to some of the world’s biggest museums, most iconic locations and, of course, the 400-year-old Canal Ring. Amsterdam is also a top international destination for conventions and conferences, and hosts an average of 650 meetings per year, which draw over 700,000 business visitors.

Visitors of all types will have plenty to do while they’re here. The city’s cultural agenda is packed with world-class exhibitions, theatre performances, live music and other unique events, and its charming neighbourhoods are full of unique shops, cafes and restaurants. The resources below will help you navigate these, and plan the right itinerary for your guests.

Most parents in the Netherlands (over 95%) have their children vaccinated. The first round is performed between the ages of 0 and 4. When they reach the age of 9, two vaccinations are repeated: DTP (diphtheria, tetanus and polio) and MMR (measles, mumps and rubella; in Dutch BMR). Girls are also offered vaccination to protect them against cervical cancer in the year they turn 13. These vaccinations are free of charge.

Conference Highlights:

·         Novel Vaccines - Research and Development

·         Cancer Vaccines

·         Vaccines Formulation & Discovery

·         DNA Vaccines

·         Novel Vaccines - Development and Production

·         Vaccine Delivery Systems and Adjuvants

·         Hepatitis, HIV and STD Vaccines

·         Vaccination for Emerging and Re-emerging Diseases

·         Biodefense Vaccine against Bioterrorism

·         Vaccines for Immune Mediated Diseases

·         Vaccines for Pregnant Women and Neonates

·         Antibodies: Engineering and Therapeutics

·         Animal Models and Clinical Trials

·         Future Challenges & Current Research

Media Partners/Collaborator/Sponsors

A huge thanks to all our amazing partners. We couldn’t have a conference without you!